Meeting
2018 ASCO Annual Meeting
Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial).
Authors
Anna Fagotti
Policlinico A. Gemelli Foundation, Rome, Italy
Anna Fagotti , Giuseppe Vizzielli , Gabriella Ferrandina , Francesco Fanfani , Valerio Gallotta , Vito Chiantera , Barbara Costantini , Pasquale Alessandro Margariti , Salvatore Gueli Alletti , Francesco Cosentino , Lucia Tortorella , Giovanni Scambia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01461850
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5516)
DOI
10.1200/JCO.2018.36.15_suppl.5516
Abstract #
5516
Poster Bd #
243
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Does aggressive surgery only benefit patients with less advanced ovarian cancer?
First Author: Shinichi Tate
First Author: Larissa Meyer
Poster
2020 Gastrointestinal Cancers Symposium
Implications of postoperative complications on survival after cytoreductive surgery and HIPEC: A multi-institutional analysis of the United States HIPEC Collaborative.
First Author: Adriana C. Gamboa
Poster
2019 ASCO Annual Meeting
Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.
First Author: Gwenael Ferron